关于“柔性显示”的报告
-
艾媒报告|2020年H1中国家电细分行业发展现状及典型企业案例分析报告
本报告研究涉及企业/品牌/案例：美的，格力，华帝，苏泊尔，格兰仕，志高；其他提及企业/品牌：苏宁易购，京东，天猫，京东，拼多多，淘宝，ME GO，五星，海尔，万和，万家乐，统帅，法迪欧，松下电器，奥克斯，TCL，海信，长虹，索尼，康佳，夏新，创维，奔腾，九阳，伊莱特，三洋，威力
2020年4月13日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020年H1中国家电细分行业发展现状及典型企业案例分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对2020年中国家电行业以及客厅、厨房、卫浴和个人用品等细分领域进行分析。此外，报告探讨产业上下游的运营模式，结合对美的、格力、华帝、苏泊尔、格兰仕和志高等典型企业的案例分析，对家电行业总体运行情况进行分析，并结合新冠疫情对2020-2021年中国家电产业发展进行趋势预判。2019年中国经济总量不断扩大，并且居民的消费支出中居住消费占比较高，这都为家电行业发展奠定了基础，并且推动家电向智能化、专业化发展，预计到2020年，中国智能家居市场规模将接近1820亿元。
In 2019, the cumulative main business income of China's household appliances increased by 4.3% year-on-year to 1.6 trillion yuan, and the cumulative total profit increased by 11.9% to 133.86 billion yuan from the previous year. From the perspective of sales channels, home appliances began to shift to online sales channels; from the perspective of sales categories, the share of smart home appliances in various sub-sectors has gradually increased; from the perspective of sales models, especially during the epidemic period, home appliance companies have increased the promotion of live broadcast e-commerce Marketing model. -
艾媒报告|2019-2021年中国5G手机行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例：华为，小米，vivo，OPPO，中国移动，中国联通，中国电信，苹果，诺基亚，魅族，三星，一加，红米，荣耀，高通，联发科，紫光展锐，英特尔，Broadcom，Skyworks，Qorvo，Murate，LG，三洋，宁德时代，比亚迪，NanoGraf，京东方，深天马A，华星光电
随着智能手机的不断普及，4G市场饱和趋势已经显现，5G商用的落地将带动5G手机发展，为手机产业带来新的活力。iiMedia Research（艾媒咨询）数据显示，预计2020-2023年将会出现5G手机的换机潮，2023年全球5G智能手机出货量将会增至40130万台。目前，华为、VO、小米等中国手机品牌都已经参与了5G市场争夺战。并且，5G手机将进一步带动产业链上下游发展，上游的元器件制造商、中游的通信设备商和下游的终端厂商都将收益，预计2025年5G相关产品和服务市场规模将达到1.15万亿元。艾媒咨询分析师认为，在政策利好、经济繁荣、技术发展和社会需求扩大的背景下，5G手机行业将会加速发展，具备较强技术实力和经济实力的玩家有望成为赛道领跑者，行业头部效应逐渐凸显。
With the continuous popularization of smart phones, the saturation trend of 4G market has emerged. The landing of 5G commercial will drive the development of 5G mobile phones and bring new vitality to the mobile phone industry. IiMedia Research (AI Media Consulting) data show that it is expected that there will be a change of 5G mobile phones in 2020-2023, and the global shipment of 5G smart phones will increase to 401.3 million units in 2023. At present, Huawei, VO, Xiaomi and other Chinese mobile phone brands have all taken part in the 5G market battle. In addition, 5G mobile phones will further drive the development of the upstream and downstream of the industrial chain. The upstream component manufacturers, the middle-stream communication equipment manufacturers and the downstream terminal manufacturers will all benefit. It is estimated that the market size of 5G related products and services will reach 1.15 trillion yuan in 2025. Ai Mei's consulting analysts believe that under the background of favorable policies, economic prosperity, technological development and expanding social demand, the 5G mobile phone industry will accelerate its development. Players with strong technological and economic strength are expected to become track leaders and the head effect of the industry will gradually become prominent. -
艾媒报告 |2019年中国柔性显示产业研究与商业投资决策分析报告
本报告研究涉及企业/品牌包括:三星、iPhone、华为、小米、OPPO、京东方、深天马A、TCL集团、微信诺、华星光电、信利国际、和辉光电、柔宇科技、中能源、湖南群显、联得装备、同兴达、志云股份、国风塑业、新纶科技、时代新材、鼎龙股份、激智科技、晶华新材、万润股份、强力新材、东旭光电、莱宝高科、长信科技、ST康得新、中颖电子、士兰微、凯盛科技、康达新材、西部材料、传艺科技、金明精机、光莆股份、样子想你才、神宇股份、海顺新材、茂硕电源
政策支持和技术进步共同推动中国柔性显示产业快速发展。iiMedia Research(艾媒咨询)监测发现，2018年中国柔性显示游产业链各个环节相关企业营收均超亿元，相关上市公司中京东方A(000725.SZ)的网络关注度最高，隆华科技(300263.SZ)的网络口碑最好。但由于技术门槛高等相关因素影响，中国柔性显示产业上游发展基础薄弱，产业存在发展不成熟、技术欠缺和市场份额不足等问题。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
